William Earnest Pullman
Direktor/Vorstandsmitglied bei USL Pharma International UK Ltd.
Profil
William Earnest Pullman is currently a Director at Proximagen Group Plc and a Director at USL Pharma International UK Ltd.
He previously worked as the Chief Medical Officer & Senior Vice President at Cubist Pharmaceuticals LLC, the Chief Development Officer & Executive VP at Dyax Corp., and the Senior Vice President-Exploratory Development at TransForm Pharmaceuticals, Inc. Pullman holds a doctorate degree from both the Australian National University and The University of Western Australia.
Aktive Positionen von William Earnest Pullman
| Unternehmen | Position | Beginn |
|---|---|---|
USL Pharma International UK Ltd.
 USL Pharma International UK Ltd. Pharmaceuticals: MajorHealth Technology USL Pharma International UK Ltd. operates as a holding company whose subsidiaries engages in the development of drugs for the treatment of neurological and inflammatory disorders. The company was founded on June 8, 2012 and is headquartered in London, the United Kingdom. | Direktor/Vorstandsmitglied | 18.12.2013 |
Proximagen Group Plc
 Proximagen Group Plc Miscellaneous Commercial ServicesCommercial Services Proximagen Group Plc engages in the business of discovery and development of therapeutic treatments. The company was founded by Jenner Peter on November 2003 and is headquartered in Cambridge, the United Kingdom. | Direktor/Vorstandsmitglied | 18.12.2013 |
Ehemalige bekannte Positionen von William Earnest Pullman
| Unternehmen | Position | Ende |
|---|---|---|
| DYAX CORP. | Technik-/Wissenschafts-/F&E-Leiter | - |
TransForm Pharmaceuticals, Inc.
 TransForm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TransForm Pharmaceuticals, Inc. develops and manufactures drugs. It integrates pharmaceutical sciences, materials science and high throughput experimentation by enabling novel technology. The company was founded by Nicholas Galakatos in 1999 and is headquartered in Lexington, MA. | Corporate Officer/Principal | - |
| CUBIST PHARMACEUTICALS INC | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von William Earnest Pullman
| Australian National University | Doctorate Degree |
| The University of Western Australia | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Dyax Corp.
 Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
Proximagen Group Plc
Proximagen Group Plc Miscellaneous Commercial ServicesCommercial Services Proximagen Group Plc engages in the business of discovery and development of therapeutic treatments. The company was founded by Jenner Peter on November 2003 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
TransForm Pharmaceuticals, Inc.
TransForm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TransForm Pharmaceuticals, Inc. develops and manufactures drugs. It integrates pharmaceutical sciences, materials science and high throughput experimentation by enabling novel technology. The company was founded by Nicholas Galakatos in 1999 and is headquartered in Lexington, MA. | Health Technology |
USL Pharma International UK Ltd.
USL Pharma International UK Ltd. Pharmaceuticals: MajorHealth Technology USL Pharma International UK Ltd. operates as a holding company whose subsidiaries engages in the development of drugs for the treatment of neurological and inflammatory disorders. The company was founded on June 8, 2012 and is headquartered in London, the United Kingdom. | Health Technology |
